U.S. pharma large copyright scrapped two experimental weight loss tablets last yr—a the moment-everyday tablet, lotiglipron, as a consequence of elevated liver enzymes as well as a 2 times-daily pill, danuglipron, as a consequence of potent side effects—but CEO Albert Bourla has repo